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Abstract 
Graft versus host disease (GVHD) is one of the most frequent and serious complications of hematopoietic stem cell 
transplantation, and is regarded as the leading cause of late mortality unrelated to the underlying malignant disease. 
GVHD is an autoimmune and alloimmune disorder that usually affects multiple organs and tissues, and exhibits a 
variable clinical course. It can manifest in either acute or chronic form. The acute presentation of GVHD is poten-
tially fatal and typically affects the skin, gastrointestinal tract and liver. The chronic form is characterized by the in-
volvement of a number of organs, including the oral cavity. Indeed, the oral cavity may be the only affected location 
in chronic GVHD. The clinical manifestations of chronic oral GVHD comprise lichenoid lesions, hyperkeratotic 
plaques and limited oral aperture secondary to sclerosis. The oral condition is usually mild, though moderate to 
severe erosive and ulcerated lesions may also be seen. The diagnosis is established from the clinical characteristics, 
though confirmation through biopsy study is sometimes needed. Local corticosteroids are the treatment of choice, 
offering overall response rates of close to 50%. Extracorporeal photopheresis and systemic corticosteroids in turn 
constitute second line treatment. Oral chronic GVHD is not considered a determinant factor for patient survival, 
which is close to 52% five years after diagnosis of the condition.
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Introduction
Before transplantation, the recipient is subjected to 
myelosuppressive and immunosuppressive conditio-
ning treatments in order to ensure that the recipient 
(host) immune system is reconstructed after grafting 
from the donor (graft) cells, thereby avoiding rejec-
tion problems. Following transplantation, however, the 
immunocompetent T lymphocytes of the donor may 
recognize as foreign the antigens expressed by the re-
cipient cells - thereby triggering an immune reaction 
accompanied by intense inflammatory responses that 
result in damage to different organs and tissues of the 
recipient. This condition is known as graft versus host 
disease (GVHD), and is a consequence of the incompa-
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tibility between the HLA system antigens of the donor 
and recipient (1).
Allogenic hematopoietic stem cell transplantation (HSCT) 
is widely used for the treatment of different benign and 
malignant hematological diseases. In this context, GVHD 
is one of the most frequent and serious complications of 
HSCT, and is regarded as the leading cause of late mor-
tality unrelated to the underlying disease process (2-4). 
Indeed, GVHD is one of the main reasons why HSCT is 
not used as often as would be desirable (5,6). GVHD is an 
autoimmune and alloimmune disorder that affects multi-
ple organs and tissues and exhibits a variable course - ad-
versely conditioning the life expectancy of those patients 
who develop the disorder (7). In the last 10 years, the inci-
dence of acute GVHD (aGVHD) has remained constant, 
while that of chronic GVHD (cGVHD) appears to have 
increased (8). This has been a consequence of the growing 
use of hematopoietic cells instead of bone marrow trans-
plants; the use of not fully HLA-compatible donors with 
or without blood ties to the recipient; the infusion of lym-
phocytes particularly in reduced intensity allotransplants; 
the number of transplants performed per year; and trans-
plantation performed in increasingly older patients (7).
The acute form of GVHD is observed in 50-70% of all 
allogenic transplant patients, while chronic GVHD is 
seen in 30-50% (9). At present, the distinction between 
these two forms of GVHD is based more on the clinical 
characteristics in each case than on timing criteria as was 
common a few years ago (2,10). The acute presentation of 
GVHD is potentially fatal and typically affects the skin, 
gastrointestinal tract and liver (11). In the chronic form 
of GVHD the oral cavity is one of the most commonly 
affected regions, and may even be the sole body location 
affected by the disease (12). Chronic GVHD usually de-
velops during the first three years after transplantation, 
and is normally preceded by the acute form. The clinical 
characteristics of cGVHD are similar to those of other 
immune mediated diseases such as lichen planus, lupus 
erythematosus or systemic sclerosis (10). Drug treatment 
for the prevention of aGVHD has no preventive effect 
upon cGVHD (7). On the other hand, there is no specific 
treatment for GVHD – the drugs of choice being corticos-
teroids followed by immune modulators (13,14).
The aim of the present study is to offer a practical update 
on oral chronic GVHD, fundamented on what we consider 
to be five key concerns in relation to this disease: (a) What 
are the risk factors for cGVHD and what is the pathogenic 
role of the T cells? (b) How often is the oral cavity affec-
ted in cGVHD? (c) In what cases would a biopsy be indi-
cated to confirm the diagnosis of oral cGVHD? (d) Is the 
treatment of oral cGVHD effective? Does it depend on 
any known factor? (e) How does oral cGVHD evolve?
A Medline-PubMed and Cochrane Collaboration litera-
ture search (latest consultation: May 2014) was conduc-
ted to clarify these issues. The search comprised publi-
cations in English and Spanish, corresponding to studies 
conducted in humans, without time restrictions, and with 
the exclusion of isolated clinical cases.
What are the risk factors for cGVHD and what 
is the pathogenic role of the T cells? 
The described risk factors for cGVHD are HLA incom-
patibility or the absence of blood ties between the donor 
and recipient; advanced age of the donor and recipient; 
a female donor and male recipient; childbirth (parity) 
in female donors (allosensitization); the transplantation 
of mobilized peripheral blood cells; the infusion of do-
nor lymphocytes; and antecedents of aGVHD (14-16). 
Advanced age, a female donor and male recipient, and 
the transplantation of mobilized peripheral blood cells 
appear to be particularly associated to cGVHD. Neither 
whole body irradiation nor the intensity of the conditio-
ning treatment before transplantation appears to influen-
ce the appearance or not of cGVHD (15).
The immunopathogenic mechanism of the disease is not 
entirely clear, though it is known that donor T cell reacti-
vity against the recipient tissues, in the form of exacerba-
ted direct or indirect inflammatory responses, is the main 
triggering factor of GVHD (4,17). Although there are 
common risk factors, the existence of certain risk factors 
that are exclusive of each type of GVHD suggests that the 
underlying pathogenesis also differs among them. In oral 
cGVHD, activation of the interferon-1 pathway appears 
to play a role (7). According to other authors, the destruc-
tion of the thymus gland by alloreactive T cells could be 
the main triggering element in cGVHD, since it seems 
that cGVHD usually does not develop after autologous 
hematopoietic cell transplantation, and thymopoiesis and 
T cell renovation phenomena moreover may be observed 
(6). It has been suggested that aGVHD is characterized 
by a Th1 lymphocyte-mediated cellular immune respon-
se, while cGVHD is characterized by a Th2 lymphocyte-
mediated humoral immune response (7). 
Both the T cells and B lymphocytes are implicated in 
the loss of general immune tolerance. The role of the B 
lymphocytes in the pathogenesis of GVHD has been ex-
plored in recent publications, due to the capacity of these 
cells to produce antibodies, and the good response obtai-
ned with anti-CD20 drugs in other autoimmune disease 
processes with characteristics similar to those of GVHD 
(17). Patients with autoantibodies and cGVHD have 
more symptoms (7,18), though no specific autoantibody 
panel for cGVHD has been established. It has also been 
suggested that cytokines such as B cell activating factor 
(BAFF, belonging to the tumor necrosis factor family), 
and antigen-presenting cells (APCs) such as the dendri-
tic cells, could also play a role (18).
The criteria that define and characterize the different 
forms of presentation of GVHD are shown in figure 1 
and in table 1.
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Table 1. Diagnostic clinical manifestations of cGVHD (10).
Fig. 1. Diagnostic distinction between acute and chronic graft-versus-host disease (10).
Organ or site cGVHD 
Common features seen with both acute and 
chronic GVHD 
Skin
Poikiloderma 
Lichen planus-like features 
Morphea-like features 
Lichen sclerosus-like features 
Erythema 
Maculopapular rash 
Pruritus
Mouth
Lichen-type features 
Hyperkeratotic plaques 
Restriction of mouth opening 
from sclerosis 
Gingivitis 
Mucositis
Erythema 
Pain 
Genitalia 
Lichen planus-like features 
Vaginal scarring or stenosis 
Gastrointestinal tract 
Esophageal web 
Strictures or stenosis in the upper 
to mid third of the esophagus 
Anorexia
Nausea
Vomiting 
Diarrhea
Weight loss 
Lung Bronchiolitis obliterans  
Liver  
Total bilirrubin, alkaline phosphatase >2 x 
upper limit of normal  
ALT or AST >2x upper limit of normal 
Muscles fascia, joints 
Fasciitis 
Joint stiffness or contractures 
secondary to sclerosis 
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How often is the oral cavity affected in cGVHD?
Although the epidemiological information referred to 
GVHD is not homogeneous, it has been estimated that 
almost one-half of all patients subjected to hematopoietic 
stem cell transplantation will develop the disease (4,7). 
The prevalence of cGVHD among those who survive 
over 100 days after transplantation is 25-80% (2,14). In 
patients who have already developed cGVHD, the oral 
cavity is affected in 70% of those who have undergo-
ne hematopoietic stem cell transplantation and in 35% 
of those who have received a bone marrow transplant 
(14,19).
The prevalence of oral cGVHD ranges between 45-83% 
(18), and the oral cavity moreover may be the only affec-
ted body region (12). 
The oral cavity, together with the skin, is one of the tar-
get organs of cGVHD, though manifestations are also 
commonly seen in the lungs, liver, genitals and gastro-
intestinal tract (2).
In what cases would a biopsy be indicated to 
confirm the diagnosis of oral cGVHD?
The consensus document published in 2005 by the Ame-
rican Society for Blood and Marrow Transplantation 
(10) defines a series of general diagnostic criteria and 
specific differential features of oral cGVHD. The pre-
sence of these general diagnostic criteria would suffice 
to diagnose cGVHD (2,10), and comprise the appearan-
ce of clinical lichenoid lesions, hyperkeratotic plaques 
and limited oral aperture secondary to sclerosis (Figs. 
2,3). The specific or distinctive clinical features in turn 
comprise xerostomia, the appearance of mucoceles, mu-
cosal atrophy, pseudomembranes and ulcers; such mani-
festations alone are not enough to establish the diagno-
sis, however.
In the presence only of the abovementioned distinctive 
clinical features, the diagnosis of oral cGVHD could be 
established without the need for a biopsy provided we 
have radiological, histological or serological confirma-
tion of the presence of cGVHD in other body organs. 
Fig. 2. Clinical features of oral cGVHD. Mouth opening restriction 
due to sclerosis (A) and lichenoid lesions on tongue (B).
A
B
Fig. 3. Clinical features of oral cGVHD. Bilateral lichenoid lesions 
affecting buccal mucosa.
However, in the presence only of the distinctive clinical 
features without disease involvement in other organs, or 
if malignancy is suspected, an oral biopsy would be in-
dicated with the purpose of establishing the diagnosis 
(17,20).
Histologically, cGVHD of the oral mucosa is characteri-
zed by the presence of dyskeratotic epithelial cells, apop-
tosis and an inflammatory infiltrate of lichenoid appea-
rance beneath the epithelial basal lamina, consisting of 
CD3+ and CD68+ T cells (17,21). Fibrosis secondary 
to collagen deposits and atrophy are the differentiating 
features of cGVHD (14).
Other oral manifestations that can appear in both the 
acute and chronic presentation of the disease are muco-
sitis, gingivitis, erythema and pain (10,22).
According to some authors and cGVHD study groups, 
the disease has similarities with other immune-mediated 
disorders such as lichen planus, lupus erythematosus, 
systemic sclerosis and Sjögren’s syndrome. In relation 
to this latter syndrome, and in the context of cGVHD, 
it has been reported that hyposalivation and xerostomia 
can manifest with some frequency as a consequence of 
progressive salivary gland atrophy. This in turn is asso-
ciated to a worsening of patient quality of life referred to 
the oral cavity, a diminished body mass index, and more 
serious manifestations such as lung involvement (23).
The pediatric presentation of oral cGVHD is rarely cha-
racterized by dry mouth, dysgeusia or dysphagia (17). 
In contrast, it is common to observe erythema, lichenoid 
lesions, atrophy, mucoceles and pseudomembranous ul-
cers. Secondary infections produced by HSV-1, Coxsac-
kie, HHV-6 and -7, and Enterovirus are also frequent. 
Phenomena such as alterations in dental root formation, 
microdontia, agenesis and malocclusion are considered 
long-term effects of HSCT in these patients (24).
With a view to standardizing the clinical, diagnostic and 
therapeutic criteria of oral cGVHD, the United States 
National Institutes of Health (NIH) in 2006 published 
a consensus document including a scale comprising a 
series of parameters that score the severity of cGVHD 
(mild, moderate, severe) and the response to treatment 
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in the different affected areas of the oral cavity (25). The 
NIH also defined a scale allowing the patients to perso-
nally reflect their situation, quantifying pain, dry mouth 
and discomfort associated with the intake of liquid and 
solid foods. In some cases, the impression of the health 
professional does not coincide with that of the patient; in 
effect, patients typically describe a situation worse than 
that described by the health professional. The resolu-
tion of cGVHD is not always associated to a substantial 
change in patient quality of life, since the latter is also 
related to other factors such as the toxic effects of the 
treatment previously prescribed for the underlying ma-
lignant disease, the effects of immunosuppressors, and 
the problems inherent to the development of cGVHD 
(26). The presence of erythematous lesions and ulcers 
confers increased severity to oral cGVHD (9). Although 
the issue is subject to controversy, recent publications 
have validated and reinforced the use of the NIH scale in 
the context of oral cGVHD (9,27). 
Is the treatment of oral cGVHD effective? Does 
it depend on any known factor?
Considering that no specific drug therapy for GVHD has 
yet been approved by the United States Food and Drug 
Administration (FDA)(4), the effectiveness of treatment 
can be expected to be limited. Furthermore, cGVHD and 
its treatment are associated to different complications 
such as secondary infections, osteoporosis, hyperten-
sion, hyperglycemia, renal failure and hyperlipidemia 
(28). In those patients who show a good response to ini-
tial treatment, the reactivation of cGVHD is observed in 
over one-half of the cases. This appears to be related to 
the severity of the disease (27).
Systemic therapy is indicated in severe cases where cGVHD 
affects a number of organs. Such treatment in turn can be 
complemented by local measures in patients with accessi-
ble lesions such as those of the skin and oral cavity.
The drugs of choice for the treatment of cGVHD are cor-
ticosteroids (class A recommendation, level of eviden-
ce Ia) with or without calcineurin inhibitors (C-1, IIa)
(2-4,14,17,18). Prednisone is recommended at a dose of 1 
mg/kg/day during two weeks, followed by 1 mg/kg on al-
ternate days during four weeks if cGVHD remains stable or 
improves. In severe cases the recommendation is to admi-
nister 1 mg/kg/day during 2-3 months and then to lower the 
dose 10-20% each month for a total of 9 months (2).
When cGVHD is found to progress despite treatment 
with prednisone 1 mg/kg/day during two weeks; re-
mains stable with ≥ 0.5 mg/kg/day of prednisone during 
4-8 weeks; or when it is not possible to lower the dose 
to under 0.5 mg/kg of prednisone a day, the disease is 
considered to be refractory to corticosteroids and the 
second- and third-line treatment options are then used. 
Specifically, the second-line treatment options comprise 
extracorporeal photopheresis (extracorporeal exposure 
of peripheral blood mononuclear cells to UVA light-acti-
vated psoralen, followed by reinfusion of the treated cells 
to the patient) and drugs such as sirolimus, everolimus, 
pentostatin, rituximab and imatinib. Third-line treatment 
in turn comprises mofetil mycophenolate, methotrexa-
te and corticosteroid pulses. Other described treatments 
for cGVHD have been less widely used and include 
hydroxychloroquine, clofazimine, cyclophosphamide, 
alemtuzumab, anti-TNFα drugs (infliximab, etanercept), 
thoraco-abdominal irradiation, thalidomide, alefacept, 
daclizumab/basiliximab, retinoids, azathioprine and me-
senchymal stem cells (2).
Inamoto et al. (26), in a study of 283 patients with 
cGVHD, recorded an overall treatment response (com-
plete remission + partial remission) of 32% during a 
follow-up period of 6 months. The organ-specific overall 
response rates were 45% in the case of the skin, 23% for 
the eyes, 32% for the oral cavity, 51% for the gastrointes-
tinal tract, and 54% in the case of the liver. The treatments 
used were prednisone associated to a calcineurin inhibi-
tor (46%), prednisone alone (22%), calcineurin inhibitors 
(18%), and other non-specified treatments (14%). Most 
of the patients presented cGVHD overlap syndrome (Fig. 
1)(83%); more than one-half had previously suffered gra-
de II-IV aGVHD; the incident and prevalent cases were 
similar in proportion (53% and 47%, respectively); and 
the most frequently affected organs were the oral cavi-
ty (61%) and skin. According to the mentioned authors, 
the scant overall response obtained may have been due 
to the fact that the treatment efficacy evaluation period 
was short. In this respect, it has been postulated that the 
results could improve over longer follow-up, since patient 
tolerance of systemic immunosuppressive therapy for 
cGVHD is generally reached after 2-3 years.
Treatment with rituximab (an anti-CD20 monoclonal 
antibody) is described as effective and safe, with very 
acceptable overall response rates, though its main incon-
venience is the appearance of side effects. The pre- or 
peri-transplant administration of rituximab offers pre-
vention against aGVHD but not against cGVHD. In 
this regard, it is believed that the early administration of 
rituximab could resolve cGVHD and moreover prevent 
the appearance of other manifestations inherent to the 
disease, though this is still only a hypothesis (29). Gu-
tiérrez-Aguirre et al. (30) analyzed the effectiveness of 
low-dose alemtuzumab (an anti-CD52 monoclonal anti-
body) and rituximab in patients refractory to corticoste-
roid therapy. After one month of treatment, the overall 
response rate was 100% - a total of 67% of the patients 
achieving partial remission and 33% total remission of 
the disease. After 90 days, 50% presented partial remis-
sion, 28% complete remission, and 21% suffered reacti-
vation of cGVHD. In this study the main affected body 
region was the oral cavity (86.7%). Kim et al. (31) admi-
nistered weekly infusions of rituximab during four wee-
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ks, followed by a monthly infusion of rituximab during 
four months. Out of a total of 37 patients, 32 responded 
positively to the treatment, with a complete response in 8 
cases and an incomplete response in 24. A total of 56.8% 
patients maintained the response to treatment during one 
year. The response was found to be greater (between 
71.4-100%) in the case of the clinical manifestations of 
the skin, oral cavity and musculoskeletal system.
As first-line treatment, Wang et al. (32) used low-dose 
oral (10 mg) or parenteral methotrexate (15 mg) with or 
without immunosuppressor therapy. After at least three 
doses of methotrexate, the overall response rate was 
83%, with complete disease remission in 62% of the pa-
tients. In the multivariate analysis, the only variable as-
sociated to increased treatment response was found to be 
involvement of a single organ. The response to metho-
trexate appears to be particularly good in cases of skin 
involvement or disease affecting a single organ without 
concomitant thrombocytopenia.
As regards local treatment, none of the different drugs 
used for this purpose can be regarded as better than the 
rest, and their efficacy is moreover poor. Nevertheless, 
topical treatment in the form of corticosteroid rinses cons-
titutes the first line of treatment for oral cGVHD (14). 
As first-line therapy, Dignan et al. (20) propose a so-
lution containing 0.5 mg of betamethasone in 10 ml of 
water retained in the oral cavity during two minutes, 
with repetition of administration three times a day. We 
can also use oral solutions of calcineurin inhibitors con-
taining cyclosporine or tacrolimus. In resistant cases the 
suggested second-line treatment options are extracorpo-
real photopheresis and systemic corticosteroids.
In the review published by Meier et al. (17), on consi-
dering the local treatment options, a solution containing 
budesonide was proposed as first choice (class C1 re-
commendation, level of evidence III-3), with a reported 
overall response rate of 83%.
Park et al. (33) compared the effectiveness of budeso-
nide (as a 0.03% aqueous solution) and dexamethasone 
(as a 0.01% aqueous solution), and recorded an overall 
response rate of 53.8% and 29.2%, respectively, after 
one month of follow-up. No statistically significant di-
fferences were recorded between the two drugs, though 
budesonide appeared to improve the pain reported by the 
patients.
The rest of topical treatment options for oral cGVHD are 
described in tables 2 and 3.
How does oral cGVHD evolve?
Chronic GVHD is the main cause of late patient mortali-
ty unrelated to malignant disease relapse (4,7,10), and is 
associated to important morbidity, a need for prolonged 
immunosuppressor therapy, functional disability, and 
impaired patient quality of life (1).
In most cases cGVHD proves extensive, affecting se-
veral organs, with moderate severity. The oral cavity is 
mostly characterized by milder disease (12,27).
The reported approximate overall survival rate is 76% 
three years (34) after the diagnosis of cGVHD, and 52% 
after 5 years (27). In pediatric patients the overall sur-
vival and disease-free survival rates 6 years after trans-
plantation are 67% and 57%, respectively (35).
Two of the factors classically regarded as having the 
greatest impact upon survival are the progressive deve-
Table 2. Topical management of oral mucosal cGVHD (1,17).
THERAPEUTICAL OPTIONS Instructions for use 
Corticosteroids 
Solution 
Dexamethasone 0.1mg/ml (5ml) 
Budesonide 0.3-0.6 mg/ml (10ml) 
Prednisolone 3mg/ml (5ml) 
Triamcinolone 1% (5ml) 
Keep solution in mouth for 
4-6 minutes without 
swallowing.
Wait 10-15 minutes before 
eating/drinking. 
Repeat up to 4-6 times per 
day. 
Gel, cream, 
and
ointment
Fluocinonide 0.05% 
Clobetasol 0.05% 
Triamcinolone 0.1-0.5% 
Apply it directly over the 
lesions 2-4 times per day 
Calcineurin inhibitors 
Solution 
Tacrolimus 0.1mg/ml (5ml) 
Cyclosporine 
Keep solution in mouth for 
4-6 minutes without 
swallowing.
Repeat up to 4-6 times per 
day. 
Ointment Tacrolimus 0.1% 
Apply it directly over the 
lesions 2-4 times per day 
Oral phototherapy Methoxypsoralen 3mg/kg + UVA light 0.5J/cm2 3-4 times per week 
Antimetabolite and 
immunosupressive agents 
Azathioprine (solution and gel) 5mg/cm3
Thalidomide (solution and ointment) 
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Table 3. Topical supportive therapies for oral cGVHD (1,17,40).
Pain 
Topical anaesthetics Lidocaine 2% (solution) 
Tetracaine, benzocaine 
CO2-laser 1W for 2-3 seconds/1mm2
Xerostomia/hyposalivation Artificial saliva 
Dentifrices, mouthrinses, gel, gums 
Electro-stimulator
Caries and periodontal 
disease 
Fluorides (dentifrices, varnish, gel) 
Oral prophylaxis and hygiene encourage 

lopment of cGVHD from prior aGVHD, and the presen-
ce of thrombocytopenia (<100,000 platelets/μl). Other 
influencing factors are the involvement of multiple body 
organs or regions, hyperbilirubinemia, and extensive 
skin involvement at the time of the diagnosis (10).
Recent publications confirm the progressive develop-
ment of cGVHD, the degree of severity, and liver and 
lung involvement as factors crucial to patient survival 
(27,34,36). Chronic overlap syndrome is likewise asso-
ciated to lesser survival and greater functional disability 
(37).
Involvement of the joints, skin and lungs in cGVHD is 
what interferes most with patient functional capacity and 
worsens quality of life. As has been mentioned, cGVHD 
frequently manifests in the oral cavity, though its appea-
rance in this location does not condition overall survival 
of the patients (34).
The prolonged and sustained immune suppression nee-
ded for the management of cGVHD (between 1-3 years)
(10), implies an increased risk of secondary infections 
and malignant processes, with an associated increase in 
mortality (4). The most prevalent secondary infections 
are of viral (HSV) and fungal origin (candidiasis), and 
exhibit unusual clinical manifestations and resistance to 
conventional therapy (38).
Hematological malignancies and lymphoproliferati-
ve disorders can be seen with some frequency and in 
early phases after HSCT. Secondary solid tumors are 
less common, though they increase over time after 
transplantation (11), with incidences of 2-6% after 10 
years and 6-13% after 15 years (39). The mean time 
from transplantation to the development of malignancy 
is 7 years (1). One-third of all secondary malignancies 
affect the skin and oral cavity (39). There is a certain 
tendency to develop tumors of epithelial origin: one half 
of them are squamous cell carcinomas – this being the 
histological variant most often seen in the oral cavity 
(11,39). The characteristics of oral squamous cell car-
cinoma in patients with antecedents of HSCT are rather 
special: the lesions develop in younger individuals; with 
no male predilection; there is usually no history of smo-
king; the tongue and cheek mucosa are the most affected 
locations; and the lesions tend to recur and develop in 
multiple locations (39). Because of these complications 
and their late onset, long-term follow-up is particularly 
indicated in patients of this kind (11).
The use of biomarkers in cGVHD is the subject of diffe-
rent investigations and clinical trials. Unfortunately, no 
biomarker panel applicable to cGVHD has been develo-
ped to date. The similarities between the normal immune 
response and cGVHD possibly complicate the identifi-
cation and application of such markers (18,35).
Conclusions
Oral cGVHD is a frequent complication of HSCT. The 
diagnosis is usually established from the clinical fin-
dings, though a biopsy is sometimes required. The di-
sorder manifests as lichenoid lesions, hyperkeratotic 
plaques and limited oral aperture secondary to sclerosis, 
and is usually mild. Locally applied corticosteroids are 
the treatment of choice and oral cGVHD is not regarded 
as a determinant factor for patient survival.
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